RxDoctor Payments Data

Yahir Santiago-Lastra, MD

Urology · San Diego, CANPI 1699936609

Payments from drug & device makers

$8,153in general payments, 2019–2025

Across 211 payments — averaging $38.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Medtronic$3K
  • Coloplast$494
  • AbbVie$301
  • Axonics, Inc.$140
  • Calyxo, Inc.$137
  • plus $490 from 13 others

What the payments were for

  • Grants$1,82722%
  • Travel & lodging$7279%
  • Food & beverage$5,47467%
  • Education$1242%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific47$3,563
Medtronic(2 entities)60$3,028
Coloplast65$494
AbbVie(2 entities)12$301
Axonics, Inc.6$140
Calyxo, Inc.1$137
Sumitomo Pharma America, Inc.5$127
Convatec Inc.3$82
Urogen Pharma, Inc.1$40
Baxter Healthcare1$37
Teleflex LLC1$36
Rochester Medical Corporation2$26
AstraZeneca1$25
Urovant Sciences Inc1$24
Johnson & Johnson1$23
ABC Home Medical Supply, Inc.1$22
180 Medical, Inc.1$18
Pfizer1$18
Laborie Medical Technologies Corp.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,153 in reported general payments places this provider in the 70th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$98,996
Medicare patients
262
Services billed
1,254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron196$194,468
MyrbetriqMirabegron82$82,373
Estradiol409$34,640
EstringEstradiol45$23,432
YuvafemEstradiol64$12,844
Methenamine Hippurate87$9,666
Gentamicin Sulfate108$5,420
Trospium Chloride20$2,443
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst33$505
Tadalafil13$489
Sodium Chloride0.9 % Sodium Chloride13$371
Tamsulosin Hcl38$273
Cephalexin29$221
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim21$54

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$127$194,468196 claims
PfizerEstring$18$23,43245 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,324 urology providers in California.

Other urology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →